TABLE 1.

Effect of K10 MAb treatment on the course and outcome of IPA in hematopoietic transplanted or neutropenic mice.

Micea	MAb treatmentb	MSTc	D/Td	Chitin content (mean μg of glucosamine ± SEM/pair of lungs)e
DBA/2 → C3H/HeJ	Control	5	8/8	49 ± 4
DBA/2 → C3H/HeJ	K10	>60f	3/8	13 ± 1g
Neutropenic DBA/2	Control	6	8/8	44 ± 5
Neutropenic DBA/2	K10	>60f	0/8	17 ± 2g

^aRecipient C3H/HeJ mice were lethally irradiated, received, transplants of T-cell-depleted BM cells from DBA/2 mice, and were infected 3 days later with 2 × 10⁷ A. fumigatus conidia that were given intranasally for 3 consecutive days. DBA/2 mice were treated with an anti-Ly6G (RB6-8C5) MAb that was given intraperitoneally at a dose of 100 μg per injection on the day before and 2 days after the first fungal intranasal inoculation.

^bControl or K10 MAb was administered intranasally at a dose of 1 μg per injection twice a day on the day before the first fungal challenge and 1, 2, and 3 days later.

^cMST, median survival time in days.

^dD/T, number of dead animals/total number of infected mice.

^eChitin content in the lungs was evaluated 1 day after the last fungal inoculation.

^fSignificantly different (P < 0.05) from the value for untreated mice as calculated by the Mann-Whitney U test.

^gSignificantly different (P < 0.05) from the value for untreated mice as calculated by Student's t test.